Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (45)

2024

  1. Additional file 1 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  2. Additional file 1 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  3. Additional file 2 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  4. Additional file 2 of “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”

    figshare

  5. Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 20, pp. 4572-4583

  6. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

    ESMO Open, Vol. 9, Núm. 8

2023

  1. European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer

    Cancer Treatment Reviews, Vol. 115

  2. In the Literature: January 2023

    ESMO Open

  3. In the Literature: March 2023

    ESMO Open

  4. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 34, Núm. 1, pp. 10-32

2022

  1. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

    Clinical Cancer Research, Vol. 28, Núm. 3, pp. 507-517

  2. Clinical management of metastatic colorectal cancer in the era of precision medicine

    CA Cancer Journal for Clinicians, Vol. 72, Núm. 4, pp. 372-401

  3. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

    Cancer Immunology, Immunotherapy, Vol. 71, Núm. 2, pp. 417-431

  4. In the literature: April 2022

    ESMO Open

  5. In the literature: December 2021

    ESMO Open

  6. In the literature: February 2022

    ESMO Open

  7. Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients

    Cancers, Vol. 14, Núm. 5

2021

  1. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

    Annals of Oncology, Vol. 32, Núm. 5, pp. 590-599

  2. First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676

  3. In the literature: August 2021

    ESMO Open